Sugi Predict

Sugi Predict / Compounds / SCHEMBL574333

SCHEMBL574333

SCHEMBL574333

Cc1c(C(=O)O)cnn1C(C)(C)C

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 4/20 0.44
▸ ALDH1A1 P00352 1/20 0.44
▸ TDP1 Q9NUW8 1/20 0.44
▸ SPR P35270 5/20 0.41
▸ POLB P06746 2/20 0.39
▸ L3MBTL1 Q9Y468 1/20 0.39
▸ MAPK1 P28482 1/20 0.38
▸ SMN1; SMN2 Q16637 2/20 0.37
▸ HSD17B10 Q99714 2/20 0.37
▸ GAA P10253 1/20 0.37
▸ TSHR P16473 1/20 0.37
▸ KMT2A Q03164 1/20 0.37
▸ TRPV4 Q9HBA0 1/20 0.37
▸ NR4A3 Q92570 1/20 0.36
▸ MAPT P10636 1/20 0.36
▸ HCAR3 P49019 1/20 0.35
▸ NR1H4 Q96RI1 1/20 0.35
▸ GABRP O00591 1/20 0.34
▸ GABRD O14764 1/20 0.34
▸ GABRA1 P14867 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL17995121 0.98 KDM4E (0.42) KDM4EALDH1A1TDP1SPRPOLB
SCHEMBL14343241 0.85 MAPK1 (0.49) KDM4EALDH1A1TDP1POLBL3MBTL1
SCHEMBL17995120 0.83 TRPV4 (0.36) KDM4EALDH1A1TDP1MAPK1SMN1; SMN2
SCHEMBL26111122 0.83 KDM4E (0.42) KDM4EALDH1A1TDP1SPRPOLB
SCHEMBL1406667 0.80 KMT2A (0.49) KDM4EALDH1A1SPRSMN1; SMN2HSD17B10
SCHEMBL17993521 0.80 SPR (0.45) ALDH1A1SPRPOLBSMN1; SMN2GAA
SCHEMBL15750714 0.79 KDM4E (0.37) KDM4EALDH1A1TDP1SPRPOLB
SCHEMBL1406800 0.79 ALKBH1 (0.37) KDM4EALDH1A1TDP1POLBL3MBTL1
SCHEMBL27646011 0.79 KDM4E (0.40) KDM4EALDH1A1TDP1POLBL3MBTL1
SCHEMBL574545 0.79 RAB9A (0.48) KDM4EALDH1A1SMN1; SMN2HSD17B10TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2295411-A1 Pyrazoles as 11-beta-hsd-1 F. Hoffmann-La Roche AG (CH) 2011-03-16 — — EP claimed
EP-1999114-A2 PYRAZOLES AS 11-BETA-HSD-1 F. Hoffmann-la Roche AG (CH) 2008-12-10 — — EP claimed
WO-2007107470-A2 PYRAZOLES AS 11-BETA-HSD-1 F. HOFFMANN-LA ROCHE AG (CH) 2007-09-27 — — WO claimed
US-20260138966-A1 WNT SIGNALING PATHWAY INHIBITORS FOR TREATMENTS OF DISEASE UNIV OF MARYLAND BALTIMORE (US) 2026-05-21 — — US disclosed
EP-4737449-A1 P53-Y220C SELECTIVE SMALL-MOLECULAR REACTIVATOR COMPOUND, PHARMACEUTICAL COMPOSITION AND USE THEREOF Changchun Genescience Pharmaceutical Co., Ltd. (CN) 2026-05-06 — — EP disclosed
US-12378220-B2 WNT signaling pathway inhibitors for treatments of disease UNIVERSITY OF MARYLAND, BALTIMORE (US) 2025-08-05 — — US disclosed
EP-3423452-B1 WNT SIGNALING PATHWAY INHIBITORS FOR TREATMENTS OF DISEASE UNIV MARYLAND (US) 2025-05-07 — — EP disclosed
WO-2025002177-A1 P53-Y220C SELECTIVE SMALL-MOLECULAR REACTIVATOR COMPOUND, PHARMACEUTICAL COMPOSITION AND USE THEREOF 长春金赛药业有限责任公司 2025-01-02 — — WO disclosed
US-20240208927-A1 WNT SIGNALING PATHWAY INHIBITORS FOR TREATMENTS OF DISEASE UNIVERSITY OF MARYLAND, BALTIMORE 2024-06-27 — — US disclosed
US-20240208927-A1 WNT SIGNALING PATHWAY INHIBITORS FOR TREATMENTS OF DISEASE UNIVERSITY OF MARYLAND, BALTIMORE 2024-06-27 — — US disclosed
US-11655233-B2 WNT signaling pathway inhibitors for treatments of disease UNIVERSITY OF MARYLAND, BALTIMORE (US) 2023-05-23 — — US disclosed
WO-2007107470-A2 PYRAZOLES AS 11-BETA-HSD-1 F. HOFFMANN-LA ROCHE AG (CH) 2007-09-27 — — WO disclosed
US-20070225280-A1 Adamantyl-pyrazole carboxamides as inhibitors of 11B-hydroxysteroid dehydrogenase ANDERSON KEVIN WILLIAM 2007-09-27 — — US disclosed
US-7015218-B1 Amide compounds and medicinal use thereof MITSUBISHI PHARMA CORPORATION (JP) 2006-03-21 — — US disclosed
EP-1176140-B1 AMIDE COMPOUNDS AND MEDICINAL USE THEREOF MITSUBISHI PHARMA CORP (JP) 2004-12-29 — — EP disclosed
EP-1176140-A1 AMIDE COMPOUNDS AND MEDICINAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2002-01-30 — — EP disclosed
EP-0151867-B1 CYANOPYRAZOLE HERBICIDES ELI LILLY AND COMPANY (US) 1990-01-10 — — EP disclosed
US-4631343-A Cyanopyrazole intermediates ELI LILLY AND COMPANY (US) 1986-12-23 — — US disclosed
US-4589905-A TERRESTRIAL AND AQUATIC APPLICATIONS ELI LILLY AND COMPANY (US) 1986-05-20 — — US disclosed
EP-0151867-A2 Cyanopyrazole herbicides ELI LILLY AND COMPANY (US) 1985-08-21 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070225280-A1 Adamantyl-pyrazole carboxamides as inhibitors of 11B-hydroxysteroid dehydrogenase HSD3B2, HSD3B1, HSD17B2 KDM4E 2951/4885ALDH1A1 132/4885TDP1 2437/4885
US-12378220-B2 WNT signaling pathway inhibitors for treatments of disease WNT1, CTNNB1, WNT3A KDM4E 3783/4885ALDH1A1 4413/4885TDP1 4381/4885
US-11655233-B2 WNT signaling pathway inhibitors for treatments of disease WNT1, CTNNB1, WNT3A KDM4E 3783/4885ALDH1A1 4413/4885TDP1 4381/4885
US-20260138966-A1 WNT SIGNALING PATHWAY INHIBITORS FOR TREATMENTS OF DISEASE CTNNB1, WNT1, CTNND1 KDM4E 2805/4885ALDH1A1 3230/4885TDP1 4819/4885
US-20240208927-A1 WNT SIGNALING PATHWAY INHIBITORS FOR TREATMENTS OF DISEASE WNT1, CTNNB1, WNT3A KDM4E 3783/4885ALDH1A1 4413/4885TDP1 4381/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.